Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
gastrointestinal tumors
Biotech
Astellas aims for CLDN18.2 gold with $1.34B licensing deal
The Japanese pharma giant is doubling down on the star solid tumor target by licensing a phase 2 ADC from Chinese biotech Evopoint.
Darren Incorvaia
May 29, 2025 7:30pm
Cancer biotech Inspirna winding down
Apr 1, 2025 3:50am
ArriVent pays Lepu $47M for GI-focused preclinical ADC
Jan 22, 2025 7:15am
JPM25: M&A strategist GSK acquires IDRx for $1B upfront
Jan 13, 2025 2:00am
GSK goes East again, snagging option on DualityBio ADC for $30M
Dec 4, 2024 8:20am
Daily aspirin use may limit spread of colorectal tumor cells
Apr 23, 2024 3:50am
